Platelet Glycoprotein Ibα Receptor Polymorphisms and Recurrent Ischaemic Events in Acute Coronary Syndrome Patients
Cite this article as: Kenny, D., Muckian, C., Fitzgerald, D.J. et al. J Thromb Thrombolysis (2002) 13: 13. doi:10.1023/A:1015307823578 Abstract Aims: To examine the relationship between polymorphisms in the platelet receptor glycoprotein (GP) Ibα and recurrent ischaemic events, and assess their impact on response to anti-platelet treatment. Methods and Results: 1014 patients presenting with unstable coronary syndrome were recruited from the OPUS-TIMI 16 clinical trial of the platelet GPIIb/IIIa antagonist, orbofiban. The subjects were genotyped for two polymorphisms in the gene for GPIbα. These were a T-5C polymorphism in the 5′ untranslated Kozak region of the GPIbα gene, and the variable number of tandem repeats (VNTR) in the macroglycopeptide region.
165 patients had events (recurrent ischaemia, urgent revascularisation, myocardial infarction (MI), stroke and death). There was no effect of the number of −5C alleles on composite endpoint frequency among Caucasian subjects (test for trend,
p = 0.47). However, MI risk increased with the number of −5C alleles carried, with MI occurring in 2.3% of patients with the −5T/−5T genotype, 5.0% of −5T/−5C, and 16.7% of −5C/−5C ( p < 0.01). The effect of treatment on MI outcome was not significantly modified by genotype (test for interaction, p = 0.10). The overall risk of bleeding was not strongly influenced by either the −5C or the VNTR polymorphisms. Conclusion: In an unstable coronary syndrome population the T-5C polymorphism in GPIbα influences risk of subsequent MI. platelets genetics myocardial infarction ischaemia glycoproteins References
Kenny D, Jónsson OG, Morateck PA, Montgomery RR. Naturally occurring mutations in glycoprotein Ibα that result in defective ligand binding and synthesis of a truncated protein.
van Zanten GH, de Graaf S, Slootweg PJ, et al. Increased platelet deposition on atherosclerotic coronary arteries.
J Clin Invest
de Feyter PJ, Ozaki Y, Baptista J, et al. Ischemia-related lesion characteristics in patients with stable or unstable angina.
Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina.
Br Heart J
Kobe B, Deisenhofer J. The leucine-rich repeat: a versatile binding motif.
Trends in Biochem Sci
López JA, Ludwig EH, McCarthy BJ. Polymorphism of human glycoprotein Iba results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region.
J Biol Chem
Kenny D, Newman PJ, Morateck PA, Montgomery RR. A dinucleotide deletion in glycoprotein Ibα results in defective membrane anchoring and circulating soluble glyco-protein Ibα in a novel form of Bernard-Soulier syndrome.
Afshar-Kharghan V, Khoshnevis-Asl M, Hopkins P, Lopez JA. Polymorphims of the platelet glycoprotein (GP) Ibα kozak sequence determines the surface level of the GP-Ib-IX-V complex and risk for early myocardial infarction.
Corral J, Lozano ML, Gonzalez-Conejero R, et al. A common polymorphism flanking the ATG codon of GPIb alpha does not affect expression and is not a major risk factor for arterial thrombosis.
Murata M, Furihata K, Ishida F, Russell SR, Ware J, Ruggeri ZM. Genetic and structural characterization of an amino acid dimorphisms in glycoprotein Ibα involved in platelet transfusion refractoriness.
Sperr WR, Huber K, Roden M, et al. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans.
Murata M, Matsubara Y, Kawano K, et al. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation.
Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP IIIa Pl
and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke.
Arterioscler Throm Vasc Biol
Gonzalez-Conejero R, Lozano ML, Rivera J, et al. Polymorphisms of platelet membrane glycoprotein Ibα associated with arterial thrombotic disease.
Cannon CP, McCabe CH, Wilcox RG, et al., for the OPUS-TIMI 16 Investigators: oral glycoprotein IIb/IIIa inhibition with orofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Ferguson JJ. Meeting highlights.
Hillmann A, Shields D, Fitzgerald DJ, Kenny D. Polymorphisms in GPIb alpha are not associated with adverse outcomes in primigravidae.
Journal of Obstetrics and Gynaecology
Morton NE. Genetic structure of forensic populations.
Proceedings of the National Academy of Science
Bacanu SA, Devlin B, Roeder K. The poer of genomic control.
Am J Hum Genet
Ishida F, Furihata K, Ishida K, et al. The largest variant of platelet glycoprotein Ibα has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine 145.
O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE trial investigators.
N Engl J Med
Graham I, Mulcahy R, Hickey N, O'Neill W, Daly L. Natural history of coronary heart disease: a study of 586 men surviving an initial acute attack.
Am Heart Journal
Bray PF. Integrin polymorphisms as risk factors for thrombosis.
Nordt TK, Peter K, Ruef J, Kubler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease.
Murata M, Kawano K, Matsubara Y, Ishikawa K, Watanabe K, Ikeda Y. Genetic polymorphisms and risk of coronary artery disease.
Semin Thromb Hemost
Google Scholar Copyright information
© Kluwer Academic Publishers 2002